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Abstract
Huntington’s disease (HD) is a progressive, neurodegenerative movement disorder. Here, we used
fast-scan cyclic voltammetry to measure dopamine release and uptake in striatal brain slices from
R6/1 HD model mice. Peak dopamine release ([DA]max) was significantly diminished in R6/1
mice (52% of wild-type at 24 weeks of age). Similarly, dopamine released per locally applied
electrical stimulus pulse ([DA]p), which is [DA]max corrected for uptake and electrode
performance, was also diminished in R6/1 mice (43% of wild-type by 24 weeks of age).
Moreover, Vmax, the maximum rate of dopamine uptake, obtained by modeling the stimulated
release plots, was decreased at 16 and 24 weeks of age in R6/1 mice (51 and 48% of wild-type,
respectively). Thus, impairments in both dopamine release and uptake appear to progress in an
age-dependent manner in R6/1 mice.
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Introduction
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder caused by
an expanded CAG repeat on the gene that encodes the huntingtin (htt) protein [1]. This
expansion results in the expression of an extended polyglutamine segment, ultimately
resulting in striatal degeneration, mood disturbances, choreic movements, and cognitive
dysfunction [2]. Dopaminergic innervation projecting from the substantia nigra pars
compacta to the striatum exerts influence over the control of intentional movement [3].
Therefore, it has been suggested that impairments in dopamine (DA) release may contribute
to the progressive motor phenotype that is characteristic of HD [4-6].
Several genetically engineered mouse strains that model HD have been used to investigate
dopaminergic system alterations. Of these, the R6/2 mouse, which possesses exon 1 of the
human huntingtin (htt) protein with about 144 CAG repeats [7-8], has been the most
extensively studied. R6/2 mice express a progressive, overt behavioral phenotype that starts
between 9 to 11 weeks of age and typically die at 10 to 13 weeks of age [7-8]. In contrast,
R6/1 mice, which also express a truncated version of the human htt, have a shorter CAG
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repeat length of about 116 repeats. Thus, overt phenotype onset begins later in life at 15 to
21 weeks of age with death occurring between 32 and 40 weeks of age [8].
Dopamine release, measured by fast-scan cyclic voltammetry (FSCV) at carbon-fiber
microelectrodes, has been shown to be impaired in striatal brain slices from R6/2 mice,
while uptake was unchanged [5]. However, studies in which exocytotic DA release was
directly measured in R6/1 mice have not been reported to our knowledge, although recent
evidence raises the possibility that dopamine system function is indeed altered. Increases in
extracellular DA induced by ip injection of malonate, an excitotoxin, are less in R6/1 mice
compared to wild-type (WT) control mice even though DA content, measured in striatal
lysates, is unchanged [9-10]. Moreover, R6/1 mice exhibit a blunted locomotor response to
amphetamine, but not apomorphine, indicating that presynaptic dysfunction of the
dopaminergic system is responsible for these behavioral alterations [10]. Nevertheless, it is
not known if DA release and uptake are altered. A clear assessment of DA release and
uptake dynamics in R6/1 mice and other HD model rodents is important because underlying
genetic differences, such as CAG repeat length, may alter nervous system function
differently between strains.
In this work, we used FSCV to investigate DA release and uptake in striatal brain slices
harvested from R6/1 mice. FSCV is useful in this case because its good temporal resolution
(10 measurements/s as applied in this work) allows for DA release and uptake to be
measured as separate processes.
Material and Methods
Animals
R6/1 [CBy.Cg-Tg(HDexon1)61b] and non-carrier control wild-type (WT) mice were
purchased from Jackson Laboratories (Bar Harbor, Maine) and were housed at the
University of Kansas animal care unit prior to use. Food and water were provided ad libitum
and a 12-hour light-dark cycle was used. All animal procedures were approved by the
University of Kansas Institutional Animal Care and Use Committee.
Brain Slice Preparation
Brain slices were prepared, as previously described, from R6/1 and WT mice at 10, 16, and
24 weeks of age [5]. Mice were anesthetized by isoflurane inhalation and then decapitated.
The brain was immediately removed and placed in ice cold artificial cerebrospinal fluid
(aCSF) consisting of 126 mM NaCl, 2.5 mM KCl, 1.2 mM NaH2PO4, 2.4 mM CaCl2, 1.2
mM MgCl2, 25 mM NaHCO3, 20 mM HEPES, and 11 mM D-Glucose with a pH of 7.4.
The aCSF was oxygenated by bubbling 95% O2/5% CO2 gas into the aCSF throughout the
experiment. After the brain was removed from the skull, the cerebellum was sliced off and
the brain was mounted on an aluminum block. Coronal slices, 300 μm thick, were made
using a vibratome slicer (Leica, Wetzlar, Germany). A single brain slice was placed in the
superfusion chamber, which was maintained at 34°C and had a continuous flow of aCSF at a
rate of 2 mL/min. Each brain slice was equilibrated in the superfusion chamber for 60
minutes prior to obtaining measurements.
DA release in brain slices
Carbon-fiber microelectrodes were fabricated as previously described [4]. Briefly, a single 7
μm diameter carbon-fiber (Goodfellow Cambridge Ltd, Huntingdon, U.K.) was aspirated
through a glass capillary tube (1.2 mm outer diameter, 0.68 mm inner diameter, 4 inches
long, A-M Systems, Inc. Carlsborg, WA, USA), and then the capillary tube was pulled using
a heated coil puller (Narishige International USA, Inc., East Meadow, NY). After the
Ortiz et al. Page 2













electrodes were trimmed to about 25 μm from the glass seal they were further insulated with
epoxy resin (EPON resin 815C, EPIKURE 3234 curing agent, Miller-Stephenson, Danbury,
CT, USA), and then cured at 100°C for 1 h. The electrodes were backfilled with 0.5 M
potassium acetate in order to provide an electrical connection between the carbon fiber and
an inserted silver wire.
A triangular waveform was applied to the carbon-fiber working electrode. The potential was
held −0.4 V, increased to +1.0 V, and then scanned back to −0.4 V at a scan rate of 300 V/s
and an update rate of 60 Hz. A headstage amplifier was interfaced with a computer via a
breakout box and custom software provided by R.M. Wightman and M.L.A.V. Heien,
University of North Carolina, Chapel Hill. A chlorided silver wire was used as an Ag/AgCl
reference electrode. The carbon fiber microelectrode was inserted to a depth of 100 μm in
the dorsolateral caudate-putamen region of the striatum between the prongs of a bipolar
stimulation electrode (Plastics One, Roanoke, VA), which was separated by a distance of
200 μm. A single electrical stimulus pulse at 60Hz was applied to the brain slice and the
current was then measured at the peak oxidation potential for dopamine (about +0.6V versus
Ag/AgCl reference electrode). Working electrodes were calibrated in a flow cell before and
after each use with dopamine standards of known concentration. These dopamine standards
were prepared by dissolving 3-hydroxytyramine hydrobromide, 99% (Sigma-Aldrich, St.
Louis, MO) solid in glucose-free aCSF. The temperature of the solutions during analysis
was 21 to 24°C. The average of the pre- and post-calibration measurements was used as the
calibration factor.
DA release measurements were collected in four locations of the dorsal lateral striatum in
each brain slice. Each release plot was then modeled using simplex minimization [11] as
previously described in Johnson et al., 2006 [5] to determine [DA]p, the peak DA release per
electrical stimulus pulse, and Vmax, the maximum uptake rate of DA by the dopamine
transporter. KM was fixed at 0.2 μm during this modeling operation. [DA]p is distinguished
from [DA]max, the peak DA release amplitude, because it is corrected for uptake and
electrode performance. Values obtained from the four sampling points were used to obtain
an average value for each slice.
Statistics
All values are represented as the average ± SEM, where n = the number of brain slices.
Statistical comparisons were made by two-way ANOVA and Bonferroni post-tests on log-
transformed data with GraphPad Prism 4.03 software (GraphPad Software, Inc., La Jolla,
CA).
Results
DA release was measured using a single pulse stimulation and FSCV at carbon-fiber
microelectrodes in brain slices harvested from R6/1 and WT mice at 10, 16, and 24 weeks
old (representative data shown in Fig. 1A). Cyclic voltammograms (CVs) obtained at the
highest point of stimulated release were used to verify that the analyte detected was DA. The
average values of [DA]max (Fig. 1B) were: 10 weeks of age, 0.82 ± 0.17 μM (R6/1; n = 9
slices from 3 mice) and 0.89 ± 0.14 μM (WT; n = 8 slices from 2 mice); 16 weeks of age,
1.03 ± 0.17 μM (R6/1, n = 16 slices from 4 mice) and 1.50 ± 0.23 μM (WT, n = 8 slices
from 2 mice); and 24 weeks of age, 0.48 ± 0.13 μM (R6/1, n = 8 slices from 3 mice) and
0.92 ± 0.14 μM (WT, n = 15 slices from 5 mice). Statistical analyses by two-way ANOVA
revealed significant genotype (F1,56 = 7.45, p < 0.01) and age (F2,56 = 6.53, p < 0.005)
effects on [DA]max. Peak stimulated DA release ([DA]max) was less in R6/1 mice than WT
control mice at 24 weeks of age (p < 0.05).
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From inspection of individual raw data release plots, it appeared that the concentration of
evoked DA decreased at a slower rate in slices from R6/1 mice than in slices from age-
matched WT mice at 16 and 24 weeks of age. This observation prompted us to model the
curves in order to calculate Vmax and [DA]p (Fig. 2A). Similar to the trend observed with
[DA]max, genotype (F1,56 = 8.03, p < 0.01) and age (F2,56 = 4.59, p < 0.05) significantly
interacted with [DA]p (Fig. 2B). The average values of [DA]p were: 10 weeks of age, 1.58 ±
0.44 μM (R6/1) and 1.67 ± 0.30 μM (WT); 16 weeks of age, 1.45 ± 0.21 μM (R6/1) and
2.13 ± 0.36 μM (WT); and 24 weeks of age, 0.66 ± 0.14 μM (R6/1) and 1.53 ± 0.27 μM
(WT). By 16 weeks of age, [DA]p, although not significant, appeared to be less in R6/1 mice
than in WT mice. At 24 weeks of age, the R6/1 mice released significantly less (p < 0.05)
DA than age-matched WT control mice. Additionally, R6/1 mice released less DA at 16
weeks of age than R6/1 mice at 24 weeks of age (p < 0.05).
The data obtained from the aforementioned modeling operation also provided us with Vmax.
The average values of Vmax were: 10 weeks of age, 10.5 ± 4.3 μM/s (R6/1) and 9.0 ± 2.3
μM/s (WT); 16 weeks of age, 4.12 ± 0.55 μM/s (R6/1) and 8.08 ± 1.99 μM/s (WT); and 24
weeks of age, 3.13 ± 0.98 μM/s (R6/1) and 6.52 ± 1.74 μM/s (WT). Genotype significantly
interacted with Vmax (F1,58 = 4.47, p < 0.05)(Fig. 2C).
Discussion
In this study, we examined DA release and uptake in R6/1 mice at 10, 16, and 24 weeks of
age. [DA]p and Vmax were determined from the best-fit parameters that were used in
modeling the stimulated release plots. These results show that [DA]max, [DA]p, and Vmax
decrease progressively over time compared to age-matched WT mice.
Our initial results indicated that [DA]max, the peak concentration of evoked DA detected at
the electrode, progressively decreased in R6/1 mice as they aged. Therefore, we modeled the
plots to determine [DA]p and Vmax. [DA]p may be considered a more reliable measure of
how much DA is released per electrical stimulus pulse because it takes into account DA
uptake and electrode performance. [DA]p also decreased with age and was significantly
diminished by 24 weeks. Complementary to our results are previous microdialysis studies
which show that basal DA levels and malonate-induced DA efflux are diminished in the
R6/1 striatum [12] even though striatal DA content is unchanged at either 16 weeks [12] or
30 weeks of age [10]. Therefore, the [DA]p values obtained using FSCV allow us to make
the more specific interpretation that the ability of dopaminergic terminals to release DA by
exocytosis is progressively impaired in R6/1 mice. These findings are similar to those found
in R6/2 mice [5]; however, consistent with having a shorter CAG repeat length, this
impairment progresses more slowly with age.
In addition to DA release, values of Vmax were decreased in R6/1 mice compared to WT
control mice. Previous labeling experiments indicate that striatal DAT expression is similar
in R6/1 and WT littermate mice [9]. Thus, decreased uptake is likely not related to a
decrease in the number of DAT protein molecules. This determination is important because
DA uptake by the DAT is known to follow Michaelis-Menten uptake kinetics and, therefore,
the equation Vmax = kcat[E]t is obeyed, where kcat is a rate constant and [E]t represents the
total enzyme concentration [13], in this case DAT. Thus, since [E]t is likely unchanged, the
difference in uptake may represent a modification of the transporter or a change in its
availability on the membrane surface. Indeed, D2 autoreceptor activation has been shown to
up-regulate DAT function [14]; nevertheless, it is unclear why Vmax is apparently unaffected
in R6/2 mice throughout the entire course of phenotype progression [5].
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In conclusion, this report reveals key malfunctions in DA release in R6/1 mice, and also
shows that the DA uptake kinetics of R6/1 differ from those of R6/2 mice, a popularly used
genetic HD model. These findings reveal potentially important considerations for
researchers studying DA system function in these HD models.
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Stimulated DA release is diminished in older R6/1 mice compared to age-matched WT
mice. (A) Representative plots of stimulated DA release in striatal brain slices from R6/1
and WT mice. The time at which the electrical stimulus pulse is applied is indicated by the
arrow. (B) Bar graph of average [DA]max measured in striatal slices from R6/1 and WT
control mice at 10, 16, and 24 weeks of age. [DA]max was significantly diminished in R6/1
mice at 24 weeks of age (*p<0.05, n= 8 R6/1 and 15 WT).
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DA release per pulse [DA]p and Vmax are decreased in R6/1 mice compared to age-matched
WT mice. (A) Representative plots and modeled curves of stimulated DA release in striatal
brain slices taken from 24-week-old R6/1 and WT mice. (B) and (C), Bar graphs of average
[DA]p and Vmax measured in striatal slices from R6/1 and WT control mice at 10, 16, and 24
weeks of age (*p<0.05, n= 8 R6/2 and 15 WT).
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